A 69-year-old woman with essential thrombocythemia (ET) developed giant ecchymosis, and she was admitted to hospital. Marked anemia (Hb 8.1 g/dl) accompanied by a prolonged activated partial thromboplastin time (89.6 s) was observed, and she received red blood cells (RBC) and fresh frozen plasma (FFP). On day 2 after admission, consciousness disturbance suddenly occurred, whereas computed tomography of the brain showed no evidence of bleeding. As the ecchymosis progressed, she developed shock. Although RBC and FFP transfusions were administered, she developed multi-organ failure and died 48 h after admission. Low factor VIII activity (<1%) accompanied by factor VIII inhibitor (17 Bethesda units) was found after her death. An autopsy revealed cerebral infarction without cerebral herniation. To date, acquired hemophilia A accompanying ET has been described in only one other patient. Although acquired factor VIII inhibitor is a rare disease, it should be tested for in ET patients with marked hemorrhagic tendency.

Keywords:
Acquired hemophilia A, Essential thrombocythemia, Factor VIII inhibitors, Hemorrhagic tendency
1.
Harrison CN: Essential thrombocythemia: challenges and evidence-based management. Br J Haematol 2005;130:153–165.
2.
Beer PA, Green AR: Essential thrombocythemia; in Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT (eds): Williams Hematology, ed 8. New York, McGraw-Hill Companies, 2010, pp 1237–1247.
3.
Elliott MA, Tefferi A: Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275–290.
4.
Franchini M, Lippi G: Acquired factor VIII inhibitors. Blood 2008;112:250–255.
5.
Green D, Lechner K: A survey of 215 non-hemophiliac patients with inhibitors to factor VIII. Thromb Haematost 1981;45:200–203.
6.
Franchini M, Targher G, Manzato F, Lippi G: Acquired factor VIII inhibitors in oncohematology: a systematic review. Crit Rev Oncol Hematol 2008;66:194–199.
7.
Sallah S, Nguyen NP, Abdallah JM, Hanrahan LR: Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med 2000;124:730–734.
8.
Kremyanskaya M, Aledort L: Acquired hemophilia: we now see it with myeloproliferative neoplasms. Am J Hematol 2011;86:329–330.
9.
Lollar P: Antibody-mediated coagulation factor deficiencies; in Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT (eds): Williams Hematology, ed 8. New York, McGraw-Hill Companies, 2010, pp 2089–2093.
10.
Mori N, Toyokawa K, Teramura M, Masuda M, Motoji T: Recombinant factor VIII-CVP therapy for acquired factor VIII inhibitors (in Japanese). Rinsho Ketsueki 2007;48:581–585.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.